Acquisition - October 5, 2020
PledPharma to acquire Rare Thyroid Therapeutics
PledPharma has entered into an agreement to acquire all outstanding shares in Rare Thyroid Therapeutics International. The purchase price for the shares in RTT consists of a cash purchase price in the amount of 60 MSEK, funded from own cash-in-hand, which will be paid on closing and a share purchase price consisting of 63,773,345 new […]
Clinical Trials - August 19, 2014
Pledpharma reports result from new study
Futility analysis in PLIANT study completed and approved by the DSMB, states Pledpharma. The futility/safety analysis of the first 30 patients has been completed and that no negative impact on the anticancer effect of the chemotherapy drug has been observed. The analysis covers the first 30 patients in the study who have completed four treatment […]